Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | TACR1 | P25103 | 11/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.68 |
| ▸ | IL1RN | P18510 | 1/20 | 0.65 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.65 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401161 | 1.00 | NMBR (0.76) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL12118582 | 1.00 | NMBR (0.76) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL11824313 | 0.93 | MAPT (0.72) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL10087951 | 0.93 | TACR1 (0.71) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL17319524 | 0.93 | NMBR (0.73) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL1318661 | 0.93 | NMBR (0.73) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL29401413 | 0.93 | NMBR (0.73) | NMBRMAPTGAAHTTTACR1 | |
| SCHEMBL3808330 | 0.93 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL1285921 | 0.93 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL29386277 | 0.93 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023069994-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9969739-B2 | Tricyclic chiral compounds and their use in asymmetric catalysis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-05-15 | — | — | US | disclosed |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | UNIV NANYANG TECH (SG) | 2016-07-21 | — | — | US | disclosed |
| US-9206090-B2 | Tricyclic chiral compounds and their use in asymmetric catalysis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-12-08 | — | — | US | disclosed |
| CN-102203097-A | Novel tricyclic chiral compounds and their use in asymmetric catalysis | UNIV NANYANG | 2011-09-28 | — | — | CN | disclosed |
| WO-2010027334-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | NMBR 2225/4885MAPT 2856/4885GAA 3732/4885 |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | COX6C, CBR3, CYCS | NMBR 3261/4885MAPT 4195/4885GAA 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.